000			03720nam a22003495i 4500
999			_c402440 _d402440
001			402440
003			ES-MaUEC
005			20240627105221.0
006			a||||fo|||| 00| 0
007			cr nn 008mamaa
008			230525s2023 sz | o |||| 0|eng d
020			_a9783031260780
024	7		_a10.1007/978-3-031-26078-0 _2doi
040			_aES-MaUEC _bspa _cES-MaUEC _dES-MaUEC
050		4	_aRM267 _b2023 EB
100	1		_aFong, I. W. _q(Ignatius W.) _eautor _4aut _4http://id.loc.gov/vocabulary/relators/aut _988388
245	1	0	_aNew Antimicrobials : _bFor the Present and the Future _cby I. W. Fong
250			_a1st ed. 2023
264		1	_aCham _bSpringer International Publishing _c2023
300			_a1 recurso en línea
336			_atexto _btxt _2rdacontent
337			_aelectrónico _bc _2rdamedia
338			_arecurso electrónico _bcr _2rdacarrier
490	0		_aEmerging Infectious Diseases of the 21st Century _x2627-5872
505	0		_a1. Antimicrobial Resistance: A crisis in the making -- 2: New Cephalosporins: 5th and 6th generations -- 3: New {esc}(Sb{esc}(B-lactam-{esc}(Sb{esc}(B-lactamase inhibitor combinations -- 4: New Glycopeptides: Televancin, dalbavancin and oritavancin -- 5: A new fluoroquinolone-Delafloxacin -- 6: New Oxazolininone---Tedizolid -- 7: New Tetracyclines: Eravacycline and Omadacycline -- 8: Pleuromutilin: A new class of antibiotic: Lefamulin -- 9: New anti-tuberculous drugs: Bedaquiline, Delamanid and Pretomanid -- 10: New systemic antifungal: Isavuconazole -- 11: Newly approved anti-parasitic drugs for malaria, fascioliasis, onchocerciasis, Chagas disease and African trypanosomiasis -- 12:New antiretroviral agents for HIV infection -- 13: New Antiviral agents for cytomegalovirus diseases -- 14: New antiviral agent for influenza: Baloxavir -- 15: Direct antiviral agents for hepatitis C -- 16: Antiviral drugs for SARS-CoV-2 and COVID-19 -- 17: New promising antimicrobials in development and novel approaches for treatment of infections.-.
520			_aThis is a timely and essential companion to the recently published Antimicrobial Resistance in the 21st Century, Second Edition. Antimicrobial resistance is a major threat to global population health, with government reports projecting it could result in over 10 million deaths in the next 35 years. Development of new agents to combat this threat is one of the WHO's top priorities, but in 2017, it conceded that the current drug development pipeline was insufficient to mitigate the threat. This book discusses recent progress and bolster new agent discovery and development, by providing researchers and students who will soon enter the field with a thorough guide to the advancements made in the last decade. Coverage includes new systemic antimicrobials approved since 2010, with detailed analysis of antibiotics, antivirals, antifungals, and antiparasitics, as well as agents in development for future use. Discussion of each drug will include its chemical nature,pharmacology/pharmacokinetics, antimicrobial spectrum, dosage, adverse reactions, drug interactions, microbial resistance, indications, clinical efficacy compared to older agents, and lists of similar agents with cost comparison. This volume is designed for researchers and students of infectious disease and medical microbiology, as well as clinicians in need of a comprehensive guide to newly developed agents.
988			_aSpringer_Medicine_2023
650		7	_2embne _9138527 _aAntibióticos
856	4	0	_uhttps://go.openathens.net/redirector/universidadeuropea.es?url=https://doi.org/10.1007/978-3-031-26078-0 _zAcceso a este recurso digital (usuarios Universidad Europea de Madrid)
942			_2lcc _cLE
998			_b06/2024 _dz _eb _zSI